Menu
Recruiting NCT05009537

Optical Genome Mapping in Hematological Malignancies

— Observational MDS ALL Other Hematologic Malignant Neoplasms

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: MDS, ALL, Other Hematologic Malignant Neoplasms. Basic parameters: No limits · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
France
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

Establish the diagnostic potential of optical genome mapping in patients with suspected hematologic cancer

Primary outcome measures

  • Establish the diagnostic potential of optical genome mapping in patients with suspected hematologic cancer [Time frame: 2021-2026]
Secondary outcome measures (2)
  • identification of new chromosomal abnormalities of clinical relevance. [Time frame: 2021-2026]
  • identification of new chromosomal anomalies involved in oncogenic pathways [Time frame: 2021-2026]

Eligibility criteria

Inclusion criteria

  • Minor/Major Patients
  • Patients with suspected hemopathies for whom we receive a sample for diagnosis in the chromosomal genetics laboratory or for whom a diagnosis of hemopathy has already been made.
  • No objection made or consent given

Exclusion criteria

  • Patients under judicial protection (guardianship, curatorship, ...),
  • Refusal to participate

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

France · 4 centers
  • CHRU de Brest — Brest
  • CH Morlaix, service d'hémato clinique — Morlaix
  • CHIC, service d'hémato clinique — Quimper
  • CH St Brieuc, service d'hémato clinique — Saint-Brieuc

Identifiers

NCT: NCT05009537 · CARTOGEN - 29BRC21.0211

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗